No Data
No Data
Xintian Pharmaceutical: 2024 Semi-Annual Report Summary
Xintian Pharmaceutical: 2024 Semi-Annual Report
Guiyang Xintian Pharmaceutical (002873.SZ): The net income in the first half of the year was 30.3395 million yuan, a year-on-year decrease of 34.51%.
Guiyang Xintian Pharmaceutical (002873.SZ) announced its semi-annual report for 2024, with total operating income of 0.442 billion yuan, a year-on-year decrease of 16.01%; net income attributable to shareholders of the listed company was 30.3395 million yuan, a year-on-year decrease of 34.51%; net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 29.513 million yuan, a year-on-year decrease of 30.33%; basic earnings per share were 0.1312 yuan.
Guiyang Xintian Pharmaceutical (002873.SZ) released its first-half performance, with a net income of 30.3395 million yuan, a decrease of 34.51%.
Guiyang Xintian Pharmaceutical (002873.SZ) released its semi-annual report for 2024, during the reporting period, the company achieved revenue...
Guiyang Xintian Pharmaceutical (002873.SZ) mainly engages in drugs for gynecological and urological diseases.
Guiyang Xintian Pharmaceutical (002873.SZ) stated on the investor interaction platform on August 12 that as a national high-tech enterprise focused on the research and development, production and sales of new Chinese patent medicines, the company has been deeply cultivating the Chinese patent medicine market since its establishment. It mainly engages in the research and development, production and sales of Chinese patent medicine products for gynecology, urology diseases, and also covers fields such as oral, breast thyroid, antipyretics, heat-clearing, blood supplementing, cardiovascular diseases and anti-tumor treatment.
Guiyang Xintian Pharmaceutical Co.,Ltd.'s (SZSE:002873) Shareholders Might Be Looking For Exit
No Data
No Data